Human Genome Epidemiology Literature Finder
|
Records 1 - 15 (of 15 Records) |
| Query Trace: Breast Neoplasms and FOXP3[original query] |
|---|
| FOXP3 germline polymorphisms are not associated with risk of breast cancer. Cancer genetics and cytogenetics 2009 Apr 190 (1): 40-2. Raskin Leon, Rennert Gad, Gruber Stephen |
| Heterozygous genetic variations of FOXP3 in Xp11.23 elevate breast cancer risk in Chinese population via skewed X-chromosome inactivation. Human mutation 2013 Feb . Zheng J, Deng J, Jiang L, Yang L, You Y, Hu M, Li N, Wu H, Li W, Li H, Lu J, Zhou Y |
| Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014 Apr 35 (4): 3785-91. Jahan Parveen, Ramachander V R Vinish, Maruthi G, Nalini S, Latha K Prasanna, Murthy T S |
| FOXP3 transcription factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer. BioMed research international 2014 2014 341654. Lopes Leandra Fiori, Guembarovski Roberta Losi, Guembarovski Alda Losi, Kishima Marina Okuyama, Campos Clodoaldo Zago, Oda Julie Massayo Maeda, Ariza Carolina Batista, de Oliveira Karen Brajão, Borelli Sueli Donizete, Watanabe Maria Angelica Eha |
| Association between FOXP3 promoter polymorphisms and cancer risk: A meta-analysis. Oncology letters 2014 Dec 8 (6): 2795-2799. Jiang Ling-Ling, Ruan Li-W |
| FOXP3 Allelic Variants and Haplotype Structures Are Associated with Aggressive Breast Cancer Subtypes. Disease markers 2017 2017 6359603. Banin Hirata Bruna Karina, Losi Guembarovski Roberta, Vitiello Glauco Akelinghton Freire, Guembarovski Alda Losi, Brajão de Oliveira Karen, Watanabe Maria Angelica Eha |
| Association of two FOXP3 polymorphisms with breast cancer susceptibility in Chinese Han women. Cancer management and research 2018 10 867-872. Tian Tian, Wang Meng, Zheng Yi, Yang Tielin, Zhu Wenge, Li Hongtao, Lin Shuai, Liu Kang, Xu Peng, Deng Yujiao, Zhou Linghui, Dai Zhij |
| Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. Oncotarget 2018 3 9 (19): 14909-14921. Tono Yasutaka, Ishihara Mikiya, Miyahara Yoshihiro, Tamaru Satoshi, Oda Hiroyasu, Yamashita Yoshiki, Tawara Isao, Ikeda Hiroaki, Shiku Hiroshi, Mizuno Toshiro, Katayama Naoyu |
| FoxP3?gene polymorphism is associated with breast cancer in Iranian patients. Experimental oncology 2018 Dec 40 (4): 309-314. Arabpour F, Shafizad A, Rahimzadeh M, Norouzan M, Naderi |
| The association of FOXP3 gene polymorphisms with cancer susceptibility: a comprehensive systemic review and meta-analysis. Bioscience reports 2019 2 39 (3): . Chen Yan, Qi Xiaoxue, Bian Ce, Ling Chen, Yi Tao, Mu Xiyan, Zhao X |
| Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. British journal of cancer 2021 Aug . Jørgensen Nanna, Hviid Thomas Vauvert F, Nielsen Lise B, Sønderstrup Ida M H, Eriksen Jens Ole, Ejlertsen Bent, Gerdes Anne-Marie, Kruse Torben A, Thomassen Mads, Jensen Maj-Britt, Lænkholm Anne-Vibe |
| FOXP3 promoter polymorphisms are not associated with a risk for breast cancer: a study from Egypt. QJM : monthly journal of the Association of Physicians 2021 May . Abdel Mawla Ahmad El Wassefy M, Fawzy I, Abdel Salam M M, Ibrahim Ismail |
| Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nature medicine 2021 1 27 (2): 250-255. Bachelot Thomas, Filleron Thomas, Bieche Ivan, Arnedos Monica, Campone Mario, Dalenc Florence, Coussy Florence, Sablin Marie-Paule, Debled Marc, Lefeuvre-Plesse Claudia, Goncalves Anthony, Reynier Marie-Ange Mouret, Jacot William, You Benoit, Barthelemy Philippe, Verret Benjamin, Isambert Nicolas, Tchiknavorian Xavier, Levy Christelle, Thery Jean-Christophe, L'Haridon Tifenn, Ferrero Jean-Marc, Mege Alice, Del Piano Francesco, Rouleau Etienne, Tran-Dien Alicia, Adam Julien, Lusque Amelie, Jimenez Marta, Jacquet Alexandra, Garberis Ingrid, Andre Fabri |
| The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO open 2024 5 9 (5): 102964. L Buisseret, Y Bareche, D Venet, E Girard, A Gombos, P Emonts, S Majjaj, G Rouas, M Serra, V Debien, E Agostinetto, S Garaud, K Willard-Gallo, D Larsimont, J Stagg, F Rothé, C Sotiri |
| Tumor microenvironmental determinants of high-risk DCIS progression. Research square 2024 5 . Alexander Borowsky, Alexa Glencer, Kirithiga Ramalingam, Nicole Schindler, Hidetoshi Mori, Parchi Ghule, Kyra Lee, Daniela Nachmanson, Adam Officer, Olivier Harismendy, Janet Stein, Gary Stein, Mark Evans, Donald Weaver, Christina Yau, Gillian Hirst, Michael Campbell, Laura Esserm |
- Page last reviewed:Feb 1, 2024
- Content source: